Results 151 to 160 of about 1,741,500 (304)

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Adjuvant Autologous Platelet-Rich Plasma Gel for Decreasing Blood Loss in Posterior Placenta Previa: A Case Series and Literature Review

Case Reports in Obstetrics and Gynecology
Chatuporn Duangkum, Wiyada Punjaruk, Thitinan Kasetthat, Hathairat Buraphaka, Jatupong Sitsutheechananon, Thanida Thanoorat   +5 more
doaj   +1 more source

Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up [PDF]

, 1997
Flynn, B, Fung, JJ, Marino, I, Mazariegos, GV, Reyes, J, Starzl, IE   +5 more
core   +1 more source

Cellular therapy in neuromyelitis optica spectrum disorder. [PDF]

Front Neurol
Zhong K, Tang Y.
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH

HemaSphere, 2022
M. Jentzsch, L. Herrmann, L. Bischof, D. Backhaus, D. Brauer, G.-N. Franke, V. Vucinic, U. Platzbecker, S. Schwind   +8 more
doaj   +1 more source

Circadian rhythm in immunotherapy and cellular therapy: impacts on the tumor microenvironment. [PDF]

Acta Biochim Biophys Sin (Shanghai)
Sun X, Qin L, Liang X, Wang D.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse. [PDF]

Blood Adv
Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ.   +27 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source